Why is the Cochlear share price slipping on Wednesday?

What's going on with Cochlear shares?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Cochlear shares dip 1.5% to $203.84 during morning trade
  • The company's shares are trading ex-dividend today
  • Eligible shareholders will receive a dividend payment of $1.45 per share on 17 October

The Cochlear Limited (ASX: COH) share price is heading south on Wednesday morning.

This comes amid the S&P/ASX 200 Index (ASX: XJO) falling wayside today after global markets dipped on the expectation that the United States Federal Reserve will lift interest rates by 75 basis points.

At the time of writing, the hearing solution company's shares are down 1.5% to $203.84.

An older woman tries to listen by cupping her ear.

Image source: Getty Images

Why are Cochlear shares falling on Wednesday?

Investors are offloading the Cochlear share price as it trades ex-dividend today.

This means if you purchased the company's shares yesterday or before, you will be eligible for the latest dividend.

However, when a company's shares trade ex-dividend, the share price tends to fall in proportion to the dividend paid out. This can also vary on how the market is tracking for the day, as well as investor sentiment.

For those eligible for Cochlear's final dividend, shareholders will receive a payment of $1.45 per share on 17 October.

The dividend is 40% franked.

Are Cochlear shares a buy now?

Following the company's financial scorecard, a number of brokers weighed in on the Cochlear share price.

As reported by ANZ Share Investing, analysts at Morgan Stanley raised its price target by 4.1% to $202 for Cochlear shares.

In addition, the team at Wilsons raised its target by 4% to $245 apiece. Based on the current share price, this implies an upside of roughly 20%.

On the other hand, Macquarie cut its rating to underperform from neutral and slashed its price target by 1.5% to $194.

This indicates a downside of 5% from where Cochlear shares trade today.

Cochlear share price summary

The Cochlear share price has dropped 13.8% over the past 12 months.

In comparison, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down around14% for the same period.

Based on today's price, Cochlear commands a market capitalisation of roughly $13.61 billion, and has a dividend yield of 1.4%.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Game over? ASX biotech stock crashes 90% on big bad news

Is it game over for this stock? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Should you buy low on these ASX healthcare stocks?

These two stocks could be poised for a bounce back.

Read more »

Woman with a concerned look on her face holding a credit card and smartphone.
Healthcare Shares

What on earth's going on with the CSL share price?

The company has long been one of the highest-quality businesses on the ASX, which makes its recent decline even more…

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

These ASX healthcare stocks are set to thrive as the population ages

A powerful demographic tailwind, but can they execute?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This drug developer could have huge upside, brokers say

Gains of more than 100% are not off the cards apparently.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

Four ASX healthcare stocks which are looking cheap

These companies could be just what the doctor ordered.

Read more »

Two health workers taking a break.
Healthcare Shares

Bell Potter is tipping this exciting ASX healthcare stock to rise 80%

An important clinical trial announcement is good news for this healthcare stock.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

Is this one of the best ASX 200 stocks money can buy?

High margins, strong growth, and global expansion have helped this ASX company stand out to me.

Read more »